Meitheal Pharmaceuticals, Inc.

BREAKING NEWS: Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated Biopharmaceutical Company Based in Chicago, Gains Exclusive U.S. Rights to YUSIMRY®, a Biosimilar of Humira®.      YUSIMRY® (adalimumab-aqvh) is FDA-approved for nine indications as a biosimilar of Humira® (adalimumab), available in both pre-filled syringe and autoinjector presentations. Demand for adalimumab products remains high. Meitheal will continue the development of both pediatric presentations and a high concentration (100mg/mL) formulation of YUSIMRY®. “Adalimumab is a critical medication for many Americans living with autoimmune conditions, and we look forward to continuing to deliver YUSIMRY®, a more affordable option to Humira®, to patients at a fair and sustainable price,” said Brian McCarthy, Meitheal Senior V.P. of Specialty. “With adalimumab biosimilars recently gaining traction, YUSIMRY® is positioned to meet the ongoing demand for accessible, treatment options due to key macro forces and the strategic investments being made in its production and commercialization.” This new, exclusive licensing agreement for YUSIMRY® adds a fifth biosimilar and the first on-market biosimilar to Meitheal’s portfolio. Meitheal’s parent company and related entities have invested over $300 million in capital and R&D in recent years to support sustainable product supply, including investing $30 million in a monoclonal antibody drug substance facility. Learn more about what is on the horizon at Meitheal in today’s news release: https://lnkd.in/gupda_6U Think sustainability, think Meitheal. * Humira® is a registered trademark of AbbVie Inc. * YUSIMRY® is a registered trademark of Hong Kong King-Friend Industry Co., Ltd. (assignment pending) and licensed to Meitheal Pharmaceuticals, Inc.

BREAKING NEWS: Meitheal Pharmaceuticals Launches Cetrorelix for Injection. We’re Meitheal Fertility, founded on the belief that everyone deserves to have a family, no matter who you are or how much money you have. Continuing with our aspiration to expand our depth and breadth within fertility, Meitheal Fertility is proud to introduce our second synthetic peptide antagonist, Cetrorelix Acetate for Injection, 0.25 mg, NDC – 71288-559-90. This product is now available in a kit that contains one glass single-dose vial (0.25 mg Cetrorelix), one pre-filled glass syringe (1 mL of Sterile Water for Injection, USP), one 20 gauge needle, and one 27 gauge needle. "We are thrilled to expand our fertility offering by bringing Cetrorelix to the United States market," declared Tom Shea, Chief Executive Officer of Meitheal Pharmaceuticals. "At Meitheal, we strive to provide affordability within our generic portfolio to increase the accessibility of products that are so important, especially within the fertility sphere. The launch of Cetrorelix is more proof of our commitment to not only providing access, but also ensuring sustainability of essential medications in the United States. By delivering on our promises, we empower our customers to effectively meet the needs of their patients." Cetrorelix is indicated for the prevention of premature ovulation in women undergoing controlled ovarian stimulation therapy followed by oocyte retrieval and assisted reproductive technology. This launch underscores Meitheal's dedication to advancing patient care and contributing to the broader healthcare landscape. For inquiries or to learn more about Cetrorelix, visit https://lnkd.in/gBaQrDxq #MeithealPharma #NewProductLaunch #PatientCare #Fertility #HealthcareInnovation

Midwest Reproductive Symposium International Chicago, IL June 5-8, 2024 Come on over to the “Windy City,” where Chicago’s rich history, sports rivalries and world class architecture make it a must-see in the summertime. Founded and headquartered in this city, Meitheal Fertility is proud to call Chicago home. This year’s Midwest Reproductive Symposium (MRSi) is taking place at Chicago’s historic Drake Hotel. Meitheal Fertility will be present at MRSi, so please stop by booth No. 13 to meet our team and learn more about Meitheal Fertility’s practical, reliable and stable perspectives on generics in the fertility space. Meitheal Fertility is bringing access and affordability to life-changing medicines, for the common good. #generics #biologics #biosimilars

BIO International Convention San Diego, CA June 3-6, 2024 “America’s Finest City,” San Diego is known for its 70 miles of pristine beaches, the world-famous San Diego Zoo, and SeaWorld San Diego. It boasts the idyllic climate and location for this year’s Bio International Convention taking place this week, at the San Diego Convention Center. Meitheal is on hand and ready to connect with biotech leaders from across the globe. Meitheal continues to bring stabilization to Generics, expand into Biologics and Biosimilars and simplify access to life-changing medicine, for the common good. Think sustainability, think Meitheal. #Generics #Biologics #Biosimilars